Stephen M. Simes (Vice-Chairman, President and Chief Executive Officer)
Mr. Simes has served as our Vice Chairman, President and Chief Executive Officer, and a director of our company since 1998.
From 1994 to 1997, Mr. Simes was President, Chief Executive Officer and a Director of Unimed Pharmaceuticals, Inc., (currently a wholly owned subsidiary of Abbott Laboratories) a company with a product focus on infectious diseases, AIDS, endocrinology and oncology. From 1989 to 1993, Mr. Simes was Chairman, President and Chief Executive Officer of Gynex Pharmaceuticals, Inc., a company which concentrated on the AIDS, endocrinology, urology and growth disorders markets. In 1993, Gynex was acquired by Savient Pharmaceuticals Inc. (formerly Bio-Technology General Corp.), and from 1993 to 1994, Mr. Simes served as Senior Vice President and director of Savient Pharmaceuticals Inc. Mr. Simes's career in the pharmaceutical industry started in 1974 with G.D. Searle & Co. (now a part of Pfizer Inc.). Mr. Simes currently serves as our designee on the board of directors of Ceregene, Inc., a privately held biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors.
Phillip B. Donenberg, CPA
(Senior Vice President, Finance, Chief Financial Officer and Secretary)
Mr. Donenberg currently serves as BioSante's Senior Vice President, Finance, Chief Financial Officer and Secretary. Prior to that he held the positions of Chief Financial Officer, Treasurer and Secretary from 1998 to 2010.
Before joining our company, Mr. Donenberg was Controller of Unimed Pharmaceuticals, Inc. (currently a wholly owned subsidiary of Abbott Laboratories) from 1995 to 1998. Prior to Unimed Pharmaceuticals, Inc., Mr. Donenberg held similar positions with other pharmaceutical companies, including Gynex Pharmaceuticals, Inc. (currently Savient Pharmaceuticals, Inc.), Applied NeuroSolutions, Inc. (formerly Molecular Geriatrics Corporation) and Xtramedics, Inc.
Michael C. Snabes, M.D., Ph.D. (Senior Vice President, Medical Affairs)
Before serving as Senior Vice President, Medical Affairs, Dr. Snabes was BioSante's Vice President, Clinical Development from 2008 to 2010 and a medical consultant to BioSante on clinical and regulatory matters since 2005. Dr. Snabes is a board certified reproductive endocrinologist, as well as holding a Ph.D. in physiology and reproductive endocrinology.
Before joining our company, Dr. Snabes was an Associate Professor in the Section of Reproductive Endocrinology and Infertility in the Department of Obstetrics and Gynecology at The University of Chicago Pritzker School of Medicine. From 2003 to 2004, Dr. Snabes served as Medical Advisor in Clinical Research and Development in Inflammation, Arthritis, and Pain at Pfizer, Inc. and from 1999-2003 in the same position at Pharmacia, Inc. where he worked on the successful development of the COX-2 inhibitors, Celebrex and Bextra. From 1997 to 1999, Dr. Snabes served as Associate Director in Clinical Research in Women's Health at Searle/Monsanto. Dr. Snabes is an elected Fellow of the American College of Obstetrics and Gynecology, the American College of Surgeons and the American College of Endocrinology. Dr. Snabes is the author of more than 135 publications and abstracts.
Sandra Croak-Brossman (Vice President of Regulatory Affairs and Quality Assurance)
Dr. Croak-Brossman joined BioSante Pharmaceuticals as the Vice President of Regulatory Affairs and Quality Assurance in July 2011.
Dr. Croak-Brossman has over 24 years of experience in the pharmaceutical industry. She has held a variety of regulatory positions and has led operations at both a U.S. and global level. From 2009 through 2011 Dr. Croak-Brossman was with Abbott Laboratories as GPRA Development Regulatory, interim head. Prior to joining Abbott, Dr. Croak-Brossman was with Pfizer, Inc. from 1994-2009 where she held various positions of increasing responsibility within the global regulatory group. Dr. Croak-Brossman's prior work experience included time at Boehringer Ingelheim and Pioneer Hi-Bred International.
Joanne Zborowski (Vice President, Clinical Development)
Ms. Zborowski has served as our Vice President of Clinical Development since 2010. Prior to this Ms. Zborowski served as Director of Clinical Development since 2007 and has been with BioSante since 2002.
Before joining our company, Ms. Zborowski began her pharmaceutical industry career with Abbott Laboratories. From 1990 to 1998, she held positions in Medical Affairs and the Pharmaceutical Products Division where she worked on neuroscience, oncology and cardiovascular indications. Ms. Zborowski held similar consulting positions from 1999-2002.
Jeffrey W. Winkelman, Ph.D., J.D. (Vice President, Intellectual Property and Contracts)
Dr. Winkelman has served as our Vice President, Oncology Programs since 2010, and as a consultant to the Company since 2009.
Before joining our Company, Dr. Winkelman was President, IP Solutions, an independent biotechnology consulting firm. From 2004 to 2008, Dr. Winkelman was the Vice President, Intellectual Property at Cell Genesys, Inc. From 1994 to 2004, Dr. Winkelman held a number of other similar positions with other biotechnology companies, including Sibia Neurosciences, Inc., Advanced Tissue Sciences, Inc. and Elitra Pharmaceuticals. Dr. Winkelman was also an associate at the IP law firm of Brown, Martin, Haller & McClain.
Patricia M. Adams, MSHR, SPHR (Vice President, Human Resources)
Ms. Adams joined BioSante Pharmaceuticals as the Vice President of Human Resources in May 2011.
Ms. Adams has over 20 years of experience in the pharmaceutical industry. From 2009 through May 2011 Ms. Adams was with Lundbeck Inc. (the US subsidiary of H. Lundbeck A/S based in Copenhagen, Denmark) where she most recently served as the Vice President of Human Resources. Prior to joining Lundbeck, Ms. Adams was employed by Takeda Pharmaceuticals North America from 1998 – 2009 where she held positions of increasing responsibility in both Human Resources and Sales Operations. Ms. Adams' previous work experiences include time at both TAP Pharmaceuticals and Abbott Laboratories.
William D. Milling, CPA (Vice President, Operations)
Currently Vice President, Operations, Mr. Milling served as our Controller from 2004 to 2007 and our Controller & Senior Director of Operations from 2008 to 2010.
Before joining our company, Mr. Milling was the Controller of Dor BioPharma from 2002 to 2004. From 1994 to 2002, Mr. Milling was with CCH, Inc. where he held various financial and systems positions of increasing responsibility.